Donna Pauler Ankerst

Summary

Affiliation: University of Texas Health Science Center
Country: USA

Publications

  1. ncbi request reprint Understanding mixed messages about prostate specific antigen: biases in the evaluation of cancer biomarkers
    Donna Pauler Ankerst
    J Urol 177:426-7. 2007
  2. ncbi request reprint New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancer
    Donna Pauler Ankerst
    Dept of Urology, University of Texas Health Science Center at San Antonio, San Antonio, USA
    Arch Ital Urol Androl 78:154-6. 2006
  3. pmc Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population
    Donna Pauler Ankerst
    Depatment of Urology, University of Texas Health Sciences Center, San Antonio, Texas, USA
    J Urol 181:2071-5; discussion 2076. 2009
  4. pmc Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group
    Donna P Ankerst
    Department of Urology, University of Texas Health Science Center at San Antonio UTHSCSA, 7703 Floyd Curl Dr, San Antonio, TX, 78229, USA
    World J Urol 32:185-91. 2014
  5. pmc Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association symptom score
    Donna P Ankerst
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX Departments of Mathematics, Technical University Munich, Garching, Germany Department of Life Sciences, Technical University Munich, Garching, Germany Electronic address
    Urology 82:1076-81. 2013
  6. pmc The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator
    Donna P Ankerst
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    J Urol 190:70-6. 2013
  7. pmc Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group
    Donna P Ankerst
    Department of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229, USA
    World J Urol 30:181-7. 2012
  8. doi request reprint Predicting prostate cancer risk through incorporation of prostate cancer gene 3
    Donna Pauler Ankerst
    Department of Urology, University of Texas Health Sciences Center, San Antonio, Texas 78229, USA
    J Urol 180:1303-8; discussion 1308. 2008
  9. pmc Trends and co-trends of prostate-specific antigen and body mass index in a screened population
    Donna P Ankerst
    Department of Urology, University of Texas, Health Science Center at San Antonio, San Antonio, TX 78229, USA
    Urology 78:10-6. 2011
  10. ncbi request reprint Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center, San Antonio, TX 78229, USA
    J Natl Cancer Inst 98:529-34. 2006

Detail Information

Publications24

  1. ncbi request reprint Understanding mixed messages about prostate specific antigen: biases in the evaluation of cancer biomarkers
    Donna Pauler Ankerst
    J Urol 177:426-7. 2007
  2. ncbi request reprint New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancer
    Donna Pauler Ankerst
    Dept of Urology, University of Texas Health Science Center at San Antonio, San Antonio, USA
    Arch Ital Urol Androl 78:154-6. 2006
    ..e., there is an ascertainment bias. We are currently performing a quantitative investigation of whether or not this ascertainment bias could explain the higher number of high-grade disease cases observed on the finasteride arm...
  3. pmc Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population
    Donna Pauler Ankerst
    Depatment of Urology, University of Texas Health Sciences Center, San Antonio, Texas, USA
    J Urol 181:2071-5; discussion 2076. 2009
    ..Prostate biopsy is often recommended based on increases in prostate specific antigen and/or abnormal digital rectal examination. We investigated the stability of a single positive test during the next 3 consecutive years...
  4. pmc Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group
    Donna P Ankerst
    Department of Urology, University of Texas Health Science Center at San Antonio UTHSCSA, 7703 Floyd Curl Dr, San Antonio, TX, 78229, USA
    World J Urol 32:185-91. 2014
    ..To assess the applicability of the Prostate Cancer Prevention Trial High Grade (Gleason grade ≥ 7) Risk Calculator (PCPTHG) in ten international cohorts, representing a range of populations...
  5. pmc Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association symptom score
    Donna P Ankerst
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX Departments of Mathematics, Technical University Munich, Garching, Germany Department of Life Sciences, Technical University Munich, Garching, Germany Electronic address
    Urology 82:1076-81. 2013
    ..To examine the effect of prostate volume, number of biopsy cores, and American Urological Association symptom score (AUASS) for prostate cancer risk assessment among men receiving finasteride in the Prostate Cancer Prevention Trial...
  6. pmc The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator
    Donna P Ankerst
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    J Urol 190:70-6. 2013
    ....
  7. pmc Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group
    Donna P Ankerst
    Department of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229, USA
    World J Urol 30:181-7. 2012
    ....
  8. doi request reprint Predicting prostate cancer risk through incorporation of prostate cancer gene 3
    Donna Pauler Ankerst
    Department of Urology, University of Texas Health Sciences Center, San Antonio, Texas 78229, USA
    J Urol 180:1303-8; discussion 1308. 2008
    ..In this report we incorporate the biomarker prostate cancer gene 3 into the Prostate Cancer Prevention Trial risk calculator...
  9. pmc Trends and co-trends of prostate-specific antigen and body mass index in a screened population
    Donna P Ankerst
    Department of Urology, University of Texas, Health Science Center at San Antonio, San Antonio, TX 78229, USA
    Urology 78:10-6. 2011
    ..This report investigated whether annual changes in body mass index (BMI) are associated with the opposite changes in prostate-specific antigen (PSA). Previous studies have confirmed lower PSA levels among men with higher BMI...
  10. ncbi request reprint Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center, San Antonio, TX 78229, USA
    J Natl Cancer Inst 98:529-34. 2006
    ..We used prostate biopsy data from men who participated in the Prostate Cancer Prevention Trial (PCPT) to develop a predictive model of prostate cancer...
  11. ncbi request reprint Effect of finasteride on the sensitivity of PSA for detecting prostate cancer
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    J Natl Cancer Inst 98:1128-33. 2006
    ..We examined the impact of finasteride on the sensitivity and area under the receiver operating characteristic curve (AUC) of prostate-specific antigen (PSA) for detecting prostate cancer...
  12. ncbi request reprint Assessment of 54 biomarkers for biopsy-detectable prostate cancer
    Dipen J Parekh
    Department of Urology, University of Texas Health Sciences Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284 7802, USA
    Cancer Epidemiol Biomarkers Prev 16:1966-72. 2007
    ....
  13. ncbi request reprint Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL
    Edith Canby-Hagino
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA
    Urology 70:748-52. 2007
    ..We assessed the risk of prostate cancer in men with a positive family history (at least one first-degree or second-degree relative), normal digital rectal examination (DRE) and a serum prostate-specific antigen (PSA) level of 4.0 ng/mL...
  14. doi request reprint Total prostate specific antigen stability confirmed after long-term storage of serum at -80C
    Amanda Beth Reed
    Department of Urology, University of Texas Health Sciences Center at San Antonio, San Antonio, Texas
    J Urol 180:534-7; discussion 537-8. 2008
    ..We characterized the long-term stability of total prostate specific antigen in serum samples after storage at -80C from 2001 until 2007...
  15. ncbi request reprint External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population
    Dipen J Parekh
    Department of Urology, University of Texas Health Science Center, San Antonio, Texas 78229, USA
    Urology 68:1152-5. 2006
    ....
  16. ncbi request reprint Biomarkers for prostate cancer detection
    Dipen J Parekh
    Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284 7802, USA
    J Urol 178:2252-9. 2007
    ..New markers that differentiate indolent from aggressive cancers to decrease potential the over treatment of prostate cancer are needed. We reviewed current and potential biomarkers for prostate cancer detection...
  17. ncbi request reprint Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification
    Donna Pauler Ankerst
    Dept of Urology, University of Texas Health Science Center at San Antonio, San Antonio, USA
    Arch Ital Urol Androl 78:125-9. 2006
    ..Lowering the PSA threshold for screening increases detection of aggressive cancer at an earlier stage, but has the unavoidable tradeoff of increased detection of the biologically irrelevant cancers...
  18. ncbi request reprint Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower
    Ian M Thompson
    Department of Urology, University of Texas Health Science Center at San Antonio, TX 78229, USA
    JAMA 294:66-70. 2005
    ..Three fourths of US men older than 50 years have been screened with prostate-specific antigen (PSA) for prostate cancer...
  19. ncbi request reprint Merging digital rectal exam, family history, age and prostate-specific antigen to create a decision-making tool
    Donna Pauler Ankerst
    Dept of Urology, University of Texas Health Science Center at San Antonio, San Antonio, USA
    Arch Ital Urol Androl 78:143-6. 2006
    ..Similarly, age, which is also a predictor of prostate cancer in the absence of other factors, did not add independent prognostic information to PSA, DRE, family history, and prior biopsy...
  20. ncbi request reprint Obesity, adipokines, and prostate cancer in a prospective population-based study
    Jacques Baillargeon
    Center for Epidemiology and Biostatistics, University of Texas Health Sciences Center at San Antonio, 78284 7802, USA
    Cancer Epidemiol Biomarkers Prev 15:1331-5. 2006
    ..The purpose of this investigation was to examine the association of obesity and the adipokines leptin, adiponectin, and interleukin-6 (IL-6) with prostate cancer risk and aggressiveness...
  21. ncbi request reprint Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial
    Carol M Moinpour
    Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center M3 C102, 1100 Fairview Ave North, Box 19024, Seattle, WA 98109 1024, USA
    J Natl Cancer Inst 99:1025-35. 2007
    ..The PCPT offered an opportunity to prospectively study the effects of finasteride and other covariates on sexual dysfunction...
  22. ncbi request reprint Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16
    Daniel P Petrylak
    Columbia University, New York, NY 10032, USA
    J Natl Cancer Inst 98:516-21. 2006
    ..We evaluated PSA changes as potential surrogate markers for survival by using data from a clinical trial...
  23. ncbi request reprint The role of adjuvant chemotherapy for patients with resected pancreatic cancer: systematic review of randomized controlled trials and meta-analysis
    Stefan Boeck
    Department of Internal Medicine III, Klinikum Grosshadern, Munich, Germany
    Oncology 72:314-21. 2007
    ..The role of adjuvant treatment strategies (including chemotherapy and chemoradiotherapy) following resection of pancreatic cancer remains controversial...
  24. ncbi request reprint Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone
    Donna L Berry
    University of Washington, Seattle, WA 98195 7266, USA
    J Clin Oncol 24:2828-35. 2006
    ..While Southwest Oncology Group trial 99-16 demonstrated a survival improvement of DE over MP, the study also was designed to compare the palliation of disease-related symptoms...